| Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
---|
Financial Royalty Assets | 1,960 | 2,065 | 2,125 | 2,198 |
---|
Intangible Royalty Assets | 143 | 171 | 37 | 1 |
---|
Other royalty income | 19 | 53 | 75 | 156 |
---|
Revenues | 2,122 | 2,289 | 2,237 | 2,355 |
---|
Provision for Other Credit Losses | - | - | 904 | 561 |
---|
Research and Development Expense | 26 | 200 | 177 | 52 |
---|
Amortization of intangible assets | 23 | 23 | 6 | - |
---|
General and Administrative Expense | 182 | 183 | 227 | 250 |
---|
Asset Impairment Charges | - | - | 616 | - |
---|
Total operating expenses, net | 527 | 859 | 1,930 | 862 |
---|
Operating income | 1,595 | 1,431 | 307 | 1,492 |
---|
Equity in (earnings)/losses of equity method investees | 44 | -19 | -9 | 29 |
---|
Interest expense | 157 | 166 | 188 | 187 |
---|
Losses/(gains) on derivative financial instruments | -42 | -22 | 97 | -2 |
---|
(Gains)/losses on equity securities | 247 | -48 | -33 | 87 |
---|
(Gains)/losses on available for sale debt securities | - | 18 | -7 | 231 |
---|
Interest income | 28 | 54 | 78 | 72 |
---|
Other non-operating expense, net | -33 | -6 | -15 | -22 |
---|
Total other (income)/expense, net | 107 | -190 | -77 | 208 |
---|
Consolidated net income before tax | 1,702 | 1,241 | 230 | 1,700 |
---|
Consolidated net income | 1,702 | 1,241 | 230 | 1,700 |
---|
Net income attributable to non-controlling interests | 727 | 621 | 187 | 565 |
---|
Net income attributable to Royalty Pharma plc | 1,702 | 1,241 | 230 | 1,700 |
---|
Earnings Per Share, Basic | 1.32 | 1.49 | 0.1 | 2.54 |
---|
Earnings Per Share, Diluted | 1.32 | 1.49 | 0.1 | 2.53 |
---|